Secondary analysis of the Stockholm Tamoxifen trials (952 ER-positive HER2-negative patients analysed): tamoxifen improved 20-year distant recurrence-free interval in luminal A (76% vs 66%) and luminal B tumours (55% vs 37%), with benefit timing differing by subtype.
Secondary analysisn = 952
Danielsson et al. Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up